Precision Underlines US FDA’s 2025 Cancer, Neuroscience Candidates

 
• By Bridget Silverman

Top areas for potential 2025 approvals were shaped by R&D focused on increasingly tightly targeted therapies, including the eight new candidates to join the still-burgeoning kinase inhibitor class and RNA interference, as well as many varieties of antibodies.

Increasingly precise and targeted interventions in disease biology are driving the highly active oncology and neuroscience drug pipelines. (Shutterstock)

More from Pink Sheet Perspectives

More from Regulatory Trackers